{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:18:33Z","timestamp":1793204313493,"version":"4.5.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate the social value of lecanemab in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The social value was evaluated using a cost-effectiveness model. The intervention was lecanemab added to the standard of care (SOC), and the comparator was SOC alone. The effect of lecanemab was determined based on the phase III trial and subsequent long-term follow-up observation studies. Health outcomes were quantified in life years and quality-adjusted life years (QALYs). Both patient and caregiver utilities were considered by summing the absolute values of utility for both the caregiver and patient. The base-case analysis was conducted from the public healthcare and long-term care payer's perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lecanemab extended the time spent in early AD, thereby maintaining quality of life (QOL), reducing caregiver burden, and medical and long-term care resource usage. The incremental QALYs were 1.31 QALYs for MCI due to AD and 0.85 QALYs for mild AD-D, and the incremental cost-effectiveness ratios (ICERs) were JPY 8.5 million \/QALY and JPY 7.9 million \/QALY ($1\u2009=\u2009JPY 150), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The value-based price or the ICER of lecanemab varied greatly depending on the perspectives and the methods of reflecting caregiver QOL. In AD, where the progression of the illness spans a long period and had a significant impact on families and society, narrowly defined value assessments were not sufficient, indicating the need to consider broader social value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877261447312","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:55:56Z","timestamp":1778475356000},"page":"283-301","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The social value of lecanemab for patients with early Alzheimer's disease in Japan"],"prefix":"10.1177","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[{"name":"Department of Health Policy and Public Health, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5623-0724","authenticated-orcid":false,"given":"Mie","family":"Azuma-Kasai","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayaka","family":"Tani","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-4410","authenticated-orcid":false,"given":"Hidetoshi","family":"Shibahara","sequence":"additional","affiliation":[{"name":"CRECON Medical Assessment Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Inoue","sequence":"additional","affiliation":[{"name":"CRECON Medical Assessment Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rothwell","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Kamanaka","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Sakata","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hiyoshi","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoyuki","family":"Tomita","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0609-7"},{"key":"e_1_3_3_3_2","unstructured":"Asada T. Prevalence of dementia and response to life dysfunction due to dementia in urban areas. Health Labour Sciences Research Grants Dementia Countermeasures Comprehensive Research Project 2011-2012 Research Report 2013."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12638"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-016-0280-8"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210075"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-141134"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00492-7"},{"key":"e_1_3_3_11_2","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. [C2H2308] lecanemab (Leqembi) https:\/\/c2\u2005h.niph.go.jp\/en\/results\/C2H2308.html (2025 accessed October 29 2025)."},{"key":"e_1_3_3_12_2","unstructured":"Central Social Insurance Medical Council. Cost-effectiveness evaluation (draft) for LEQEMBI December 13 2023 https:\/\/www.mhlw.go.jp\/content\/12404000\/001178603.pdf (2023 accessed October 28 2025)."},{"key":"e_1_3_3_13_2","unstructured":"Central Social Insurance Medical Council. Regarding the handling of the \u201cposition of public medical care and nursing care\u201d regarding the cost-effectiveness evaluation of LEQEMBI July 6 2025 https:\/\/www.mhlw.go.jp\/content\/10808000\/001533242.pdf (2025 accessed October 28 2025)."},{"key":"e_1_3_3_14_2","unstructured":"Bank of Japan. Bank of Japan: Basic exchange rate December 2024 https:\/\/www.boj.or.jp\/about\/services\/tame\/tame_rate\/kijun\/kiju2412.htm (2024 accessed 22 May 2025)."},{"key":"e_1_3_3_15_2","article-title":"Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price","volume":"8","author":"Sinha P","year":"2022","unstructured":"Sinha P, Barocas JA. Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price. Alzheimers Dement (N Y) 2022; 8: e12256.","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.442"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00463-7"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0315"},{"key":"e_1_3_3_19_2","unstructured":"Medical Data Vision Co. Ltd. MDV EBM insight https:\/\/en.mdv.co.jp\/ebm\/ (accessed 23 May 2025)."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.8.1091"},{"key":"e_1_3_3_21_2","unstructured":"Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative https:\/\/adni.loni.usc.edu\/ (accessed 23 May 2025)."},{"key":"e_1_3_3_22_2","unstructured":"Eisai Co. Ltd. Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer\u2019s Disease? presented at Alzheimer's Association International Conference (AAIC) 2024. https:\/\/www.eisai.co.jp\/ir\/library\/presentations\/pdf\/4523_240731_1.pdf (accessed 23 May 2025)."},{"key":"e_1_3_3_23_2","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study","volume":"21","author":"van Dyck CH","year":"2025","unstructured":"van Dyck CH, Sperling R, Johnson K, et al. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study. Alzheimers Dement 2025; 21: e70905.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00272-1"},{"key":"e_1_3_3_25_2","unstructured":"Ministry of Health Labor and Welfare. Abridged Life Tables for Japan 2022 https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/life22\/index.html (accessed 27 August 2024)."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S64107"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1922369"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-201514"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.03.010"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-01629-1"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00723-1"},{"key":"e_1_3_3_32_2","unstructured":"Association of People with Dementia and their Families. A Survey of the Thoughts and Caregiving Situation of People with Dementia and Their Families and Citizens\u2019 Awareness of Dementia. 2019 https:\/\/alzheimer.or.jp\/wp-content\/uploads\/2020\/04\/rouken2019.pdf (accessed 21 August 2024)."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1720068"},{"key":"e_1_3_3_34_2","unstructured":"Institute for Clinical and Economic Review. Lecanemab for Early Alzheimer's Disease Final Evidence Report. 2023 https:\/\/icer.org\/wp-content\/uploads\/2023\/04\/ICER_Alzheimers-Disease_Final-Report_For-Publication_04172023.pdf (accessed 21 August 2024)."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01164-4"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01321-3"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.894"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170518"},{"key":"e_1_3_3_39_2","unstructured":"Ministry of Health Labor and Welfare. Guideline for Promotion of Optimal Use (Recanemab [Genetic Recombination]) As of December 2023. https:\/\/www.mhlw.go.jp\/content\/001180610.pdf (accessed 30 July 2024)."},{"key":"e_1_3_3_40_2","first-page":"381","article-title":"Medical and long-term care costs of Alzheimer's disease in Japan according to Clinical Dementia Rating Scores: the LIFE Study","volume":"9","author":"Kim SA","year":"2026","unstructured":"Kim SA, Oda F, Maeda M, et al. Medical and long-term care costs of Alzheimer's disease in Japan according to Clinical Dementia Rating Scores: the LIFE Study. JMA J 2026; 9: 381\u2013384.","journal-title":"JMA J"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14336"},{"key":"e_1_3_3_42_2","article-title":"Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"van der Kall LM","year":"2021","unstructured":"van der Kall LM, Truong T, Burnham SC, et al. Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Lancet Neurol 2021; 96: e662\u2013e670.","journal-title":"Lancet Neurol"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01494-9"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.122"},{"key":"e_1_3_3_45_2","volume-title":"Result of the drug price revision based on the cost-effectiveness evaluation (Lecanemab)614th General Meeting of the Central Social Insurance Medical Council (Chuikyo)","author":"Ministry of Health, Labour and Welfare","unstructured":"Ministry of Health, Labour and Welfare. Result of the drug price revision based on the cost-effectiveness evaluation (Lecanemab). In: 614th General Meeting of the Central Social Insurance Medical Council (Chuikyo), Published 6 August, 2025, https:\/\/www.mhlw.go.jp\/content\/10808000\/001533241.pdf (2025, accessed 2 March 2026)."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.012"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.03.009"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2020.102346"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1639186"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261447312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877261447312","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261447312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T09:12:22Z","timestamp":1782810742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877261447312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/13872877261447312"],"URL":"https:\/\/doi.org\/10.1177\/13872877261447312","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}